Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
| ▸ | HPGDS | O60760 | 6/20 | 0.44 |
| ▸ | CTSA | P10619 | 3/20 | 0.43 |
| ▸ | FCER2 | P06734 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031128 | 0.89 | SCN9A (0.48) | SCN9ACTSAROCK2ROCK1CNR2 | |
| SCHEMBL5032419 | 0.84 | SCN9A (0.46) | SCN9ACTSACNR2 | |
| SCHEMBL5034282 | 0.84 | CAPN1 (0.42) | SCN9AHPGDSFCER2MMP3MMP9 | |
| SCHEMBL4136209 | 0.80 | EGLN1 (0.41) | — | |
| SCHEMBL13927645 | 0.79 | CNR2 (0.42) | SCN9ACTSAROCK2ROCK1CNR2 | |
| SCHEMBL4149599 | 0.78 | MAP2K4 (0.52) | — | |
| SCHEMBL4136211 | 0.77 | MAP2K4 (0.45) | — | |
| SCHEMBL13927646 | 0.76 | CTSA (0.43) | CTSACNR2 | |
| SCHEMBL13927643 | 0.75 | MAP4K4 (0.46) | — | |
| SCHEMBL4149434 | 0.75 | DYRK1A (0.52) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | SCN9A 2678/4885HPGDS 3567/4885CTSA 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.